Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

OBJECTIVE: To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD). METHODS: Safety data from clinical trials of upadacitinib 15 mg and upadacitinib 30 mg (AD only) for treating RA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Cohen, Stanley B, Winthrop, Kevin L, Nash, Peter, Irvine, Alan D, Deodhar, Atul, Mysler, Eduardo, Tanaka, Yoshiya, Liu, John, Lacerda, Ana P, Palac, Hannah, Shaw, Tim, Mease, Philip J, Guttman‑Yassky, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923346/
https://www.ncbi.nlm.nih.gov/pubmed/36754548
http://dx.doi.org/10.1136/rmdopen-2022-002735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923346/
https://www.ncbi.nlm.nih.gov/pubmed/36754548
http://dx.doi.org/10.1136/rmdopen-2022-002735

Ejemplares similares